Stock LLY ELI LILLY AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		After market 07:14:38 pm
733.5 USD +1.19% Intraday chart for Eli Lilly and Company 734 +0.07%
Apr. 25 Scholz pledges further support for the pharmaceutical industry DP
Apr. 25 Scholz promises support for pharma sector in Germany as Merck invests RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 126,190 153,067 250,419 347,613 524,224 660,721 - -
Enterprise Value (EV) 1 139,069 165,981 263,395 361,640 546,522 675,911 671,462 669,325
P/E ratio 14.8 x 24.9 x 45.1 x 53 x 101 x 60.5 x 40.9 x 31.6 x
Yield 1.96% 1.75% 1.23% 1.07% 0.78% 0.71% 0.81% 0.89%
Capitalization / Revenue 5.65 x 6.24 x 8.84 x 12.2 x 15.4 x 16 x 12.9 x 10.9 x
EV / Revenue 6.23 x 6.76 x 9.3 x 12.7 x 16 x 16.3 x 13.1 x 11 x
EV / EBITDA 18.4 x 19.3 x 26.3 x 38.2 x 63.7 x 45.3 x 32.2 x 25.1 x
EV / FCF 36.6 x 32.5 x 44.3 x 69.1 x 690 x 80.6 x 50.6 x 38.3 x
FCF Yield 2.73% 3.08% 2.26% 1.45% 0.15% 1.24% 1.97% 2.61%
Price to Book 48.3 x 28.6 x 29.4 x 32.7 x 48.9 x 38.3 x 24.2 x 16.2 x
Nbr of stocks (in thousands) 960,131 906,582 906,592 950,178 899,307 900,766 - -
Reference price 2 131.4 168.8 276.2 365.8 582.9 733.5 733.5 733.5
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,320 24,540 28,318 28,541 34,124 41,355 51,278 60,657
EBITDA 1 7,551 8,589 10,005 9,472 8,584 14,911 20,878 26,644
EBIT 1 6,079 7,265 8,457 7,950 7,057 13,419 19,237 24,929
Operating Margin 27.24% 29.6% 29.86% 27.85% 20.68% 32.45% 37.51% 41.1%
Earnings before Tax (EBT) 1 5,266 7,230 6,156 6,806 6,555 12,689 17,346 20,181
Net income 1 8,318 6,194 5,582 6,245 5,240 10,864 15,778 20,649
Net margin 37.27% 25.24% 19.71% 21.88% 15.36% 26.27% 30.77% 34.04%
EPS 2 8.890 6.790 6.120 6.900 5.800 12.12 17.94 23.18
Free Cash Flow 1 3,803 5,112 5,951 5,230 792.5 8,386 13,259 17,469
FCF margin 17.04% 20.83% 21.01% 18.32% 2.32% 20.28% 25.86% 28.8%
FCF Conversion (EBITDA) 50.36% 59.52% 59.48% 55.21% 9.23% 56.24% 63.5% 65.56%
FCF Conversion (Net income) 45.71% 82.53% 106.61% 83.75% 15.12% 77.19% 84.03% 84.6%
Dividend per Share 2 2.580 2.960 3.400 3.920 4.520 5.178 5.977 6.564
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 6,773 8,000 7,810 6,488 6,942 7,302 6,960 8,312 9,499 9,353 8,930 9,844 10,716 11,788 10,745
EBITDA 1 2,446 2,982 3,046 1,679 2,373 2,375 1,982 2,618 986.4 2,855 2,827 3,002 3,783 4,475 -
EBIT 1 2,064 2,536 2,610 1,330 2,010 2,000 1,620 2,252 575.4 2,468 2,674 2,973 3,589 4,161 -
Operating Margin 30.48% 31.7% 33.42% 20.5% 28.96% 27.39% 23.27% 27.09% 6.06% 26.38% 29.94% 30.2% 33.49% 35.29% -
Earnings before Tax (EBT) 1 1,245 - - - - - - 2,089 427.2 2,509 2,455 2,629 3,314 3,961 -
Net income 1 1,110 1,726 1,903 952.5 1,452 1,938 1,345 1,763 -57.4 2,190 2,058 2,370 2,879 3,504 -
Net margin 16.39% 21.58% 24.36% 14.68% 20.91% 26.54% 19.32% 21.21% -0.6% 23.41% 23.05% 24.08% 26.86% 29.72% -
EPS 2 1.220 1.900 - 1.050 1.610 2.140 1.490 1.950 -0.0600 2.420 2.440 2.604 3.258 3.777 -
Dividend per Share 2 0.8500 0.8500 0.9800 0.9800 0.9800 0.9800 1.130 1.130 1.130 1.130 1.182 1.182 1.182 1.182 1.029
Announcement Date 10/26/21 2/3/22 4/28/22 8/4/22 11/1/22 2/2/23 4/27/23 8/8/23 11/2/23 2/6/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,879 12,914 12,976 14,027 22,298 15,190 10,741 8,604
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.706 x 1.504 x 1.297 x 1.481 x 2.598 x 1.019 x 0.5145 x 0.3229 x
Free Cash Flow 1 3,803 5,112 5,951 5,230 793 8,386 13,259 17,469
ROE (net income / shareholders' equity) 89.6% 175% 102% 73.2% 48.9% 78.4% 76.8% 70.7%
ROA (Net income/ Total Assets) 13.4% 14.4% 15.6% 14.6% 9.23% 16.8% 20.9% 24.8%
Assets 1 62,143 42,961 35,816 42,708 56,748 64,689 75,347 83,354
Book Value Per Share 2 2.720 5.900 9.410 11.20 11.90 19.10 30.30 45.20
Cash Flow per Share 2 5.170 7.120 7.960 7.830 4.690 15.00 19.80 25.10
Capex 1 1,034 1,388 1,310 1,854 3,448 2,525 2,518 2,457
Capex / Sales 4.63% 5.66% 4.63% 6.5% 10.1% 6.11% 4.91% 4.05%
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
733.5 USD
Average target price
813.3 USD
Spread / Average Target
+10.88%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
PFIZER, INC. Stock Pfizer, Inc.
-11.77% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. Financials Eli Lilly and Company